In vivo delivery of miRNAs for cancer therapy: challenges and strategies
Abstract MicroRNAs (miRNAs), small non-coding RNAs, can regulate post-transcriptional
gene expressions and silence a broad set of target genes. miRNAs, aberrantly expressed in …
gene expressions and silence a broad set of target genes. miRNAs, aberrantly expressed in …
[HTML][HTML] The double edge sword of fibrosis in cancer
C Chandler, T Liu, R Buckanovich, LG Coffman - Translational Research, 2019 - Elsevier
Cancer-associated fibrosis is a critical component of the tumor microenvironment (TME)
which significantly impacts cancer behavior. However, there is significant controversy …
which significantly impacts cancer behavior. However, there is significant controversy …
[HTML][HTML] Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival
BC Özdemir, T Pentcheva-Hoang, JL Carstens… - Cancer cell, 2014 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal
myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the …
myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the …
MYC instructs and maintains pancreatic adenocarcinoma phenotype
The signature features of pancreatic ductal adenocarcinoma (PDAC) are its
fibroinflammatory stroma, poor immune activity, and dismal prognosis. We show that acute …
fibroinflammatory stroma, poor immune activity, and dismal prognosis. We show that acute …
Targeting pancreatic stellate cells in cancer
Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and
resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis …
resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis …
[HTML][HTML] Role of pancreatic stellate cells in chemoresistance in pancreatic cancer
JA McCarroll, S Naim, G Sharbeen, J Lee… - Frontiers in …, 2014 - frontiersin.org
Pancreatic cancer is highly chemoresistant. A major contributing factor is the characteristic
extensive stromal or fibrotic reaction, which comprises up to 90% of the tumor volume. Over …
extensive stromal or fibrotic reaction, which comprises up to 90% of the tumor volume. Over …
[HTML][HTML] The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
DS Houg, MF Bijlsma - Molecular cancer, 2018 - Springer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive
malignancies to date, largely because it is associated with high metastatic risk. Pancreatic …
malignancies to date, largely because it is associated with high metastatic risk. Pancreatic …
[HTML][HTML] Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with
a dismal prognosis for most patients. Fibrosis and inflammation are hallmarks of tumor …
a dismal prognosis for most patients. Fibrosis and inflammation are hallmarks of tumor …
[HTML][HTML] Three-dimensional cell culture systems in radiopharmaceutical cancer research
A Doctor, V Seifert, M Ullrich, S Hauser, J Pietzsch - Cancers, 2020 - mdpi.com
Simple Summary Cancer cells cultured in three-dimensional (3D) model systems exhibit
physiologically relevant cell–cell and cell–matrix interactions, gene expression patterns, and …
physiologically relevant cell–cell and cell–matrix interactions, gene expression patterns, and …
[HTML][HTML] Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs
Pancreatic cancer is predicted to be the second leading cause of cancer-related death by
2025. The best chemotherapy only extends survival by an average of 18 weeks. The …
2025. The best chemotherapy only extends survival by an average of 18 weeks. The …